Epimune completes CE-marking of first IVD product

Epimune today completed CE-marking of its first in vitro diagnostic (IVD) test, the i.Mune TBNK Test, with the signing of the declaration of conformity and registration with the German Institute for Medical Documentation and Information (DIMDI). This is another milestone in the short history of our company, which started operations in April 2019.

Epimune's started crowdinvestment campaign on Seedmatch (German only)

Epimune started a crowdinvestment campaign on Seedmatch on 28 May 2020. Already, more than 250 investors decided to support Epimune. A heartfelt thank you to all of them! Read more about our campaign on Seedmatch (sorry guys - German only!)

Studies show - immune cell quantification can help to predict COVID-19 disease course

Severe courses of corona virus infections are characterized by dramatic decreases in lymphocyte counts. Read here how Epimune's i.Mune™ TBNK test can help to monitor infected individuals using dried-blood spot (DBS) testing. 

Pioneering Molecular Immune Cell Quantification

Epimune’s goal is to revolutionize diagnosis and monitoring of patients with disorders of the immune system 


Using epigenetics, Epimune develops & commercializes molecular diagnostic tests for immune cell quantification from a drop of blood